Business Wire

CA-ALKIRA,-INC.

13.4.2021 10:02:11 CEST | Business Wire | Press release

Share
Alkira Teams Up with Microsoft to Transform the Cloud Networking Journey to Azure

Network Cloud pioneer Alkira® today announced a close collaboration with the Microsoft for Startups program, a select group of emerging businesses hand-picked by Microsoft for the benefits they offer to Microsoft Azure customers in their journey to the cloud. The select start-ups receive growth partnership and ecosystem support from Microsoft including access to technical, sales and marketing opportunities and leadership. Alkira also announced that the Alkira Cloud Services Exchange (CSX) – the core of the company’s Network Cloud platform – is now available on the Azure Marketplace.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005521/en/

The Alkira Network Cloud platform which reduces the time, cost and complexity of connectivity cloud environments, provides Azure customers with increased performance, manageability and security when deploying Windows workloads in the Azure cloud. Microsoft Azure customers can access Alkira’s solution in Azure, or in a multi-cloud network alongside other best-of-breed products in the Azure Marketplace.

Benefitting from the underlying power of Azure, Alkira CSX is delivered as a secure cloud networking infrastructure as-a-service that dynamically scales according to customers’ needs and reduces the time taken to deploy cloud networks from months to minutes.

Amir Khan, Chief Executive Officer and Founder of Alkira, said: “The time, cost and complexity of building networks in the cloud with end-to-end security and management visibility are major challenges holding back digital transformation. Our service was developed to help businesses overcome the trade-offs, complexity and long lead times associated with cloud networking. The Alkira Network Cloud platform accelerates the deployment and simplifies the management of cloud workloads, leaving customers free to focus on the objectives of their business. We’re excited to be deepening our relationship with Microsoft through the Microsoft for Startups program and to be able to offer those benefits to the growing number of organizations seeking transformational solutions from the Azure Marketplace.”

Jeff Ma, General Manager of Microsoft for Startups, commented: “Our start-up program gives new businesses access to the incredible resources of Microsoft and helps to bring the benefits of exciting new technologies like Alkira’s Network Cloud platform to Microsoft’s Azure customers. Alkira’s platform provides a powerful and flexible set of capabilities to leverage the power of Azure to deploy fully featured cloud networks.”

Mamoon Hamid, Partner at Kleiner Perkins added: “It’s time for the network to join the cloud era, and Alkira’s Cloud Networking Infrastructure as-a-Service provides customers a secure, simplified path to the Microsoft Azure cloud. Microsoft is progressively offering companies like Alkira the opportunity to help Azure customers on their cloud journey, and we're already seeing it unlock value for everyone involved."

Brad Casemore, Research Vice President, Datacenter Networks at IDC said: “IDC finds that enterprises are gaining greater appreciation of how modern infrastructure can support strategic cloud objectives such as business agility, application experience, robust security. That said, while enterprise architects want to help their organizations achieve greater business agility through the migration of workloads to cloud, they also want to ensure that the transition doesn’t entail compromises to operational control and management. Alkira’s Network Cloud platform addresses these requirements by helping organizations and their architects reconcile the business benefits of cloud with the need for effective control.”

Microsoft customers who access Alkira’s Network Cloud through Azure Marketplace benefit from reduced procurement overheads, simplified billing and quicker deployment, as well as the assurance of Microsoft certification.

For more information:

About Alkira

Alkira® developed the Network Cloud which enables Enterprises to build and deploy a global unified Cloud Network Infrastructure as-a-Service (CNaaS) that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira Cloud Services Exchange™ (CSX) seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of Integrated Solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.Alkira.com or follow us @AlkiraNet

Alkira® is a registered trademark and Alkira Cloud Services Exchange™ is a trademark of Alkira, Inc. All other marks are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/alkirainc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye